Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Summary

This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after progression on PD-1 or PD-L1 targeted antibodies. Plinabulin blocks tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving plinabulin in combination with radiation therapy and immunotherapy may work better in treating advanced cancers.

Timeline

Start

2021-04-14

Primary completion

2025-02-27

Completion

2025-02-27

Publications

• Lin SH, Subbiah V, Neri S, Cohen EN, Li Z, Lu YJ, Son YL, Lyu Y, Braun C, Gao H, Jayachandran G, Sharma A, Ye R, Fang P, Li N, Karp D, Hong D, Rodon J, Yu H, Peng J, Lloyd GK, Tonra JR, Reuben JM, Huang L, Fu S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med. 2025 Oct 10;6(10):100752. doi: 10.1016/j.medj.2025.100752. Epub 2025 Jun 27.

Drugs

Indications